<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e74e2e25-66da-4c49-9c26-44c409e14d40"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use BYLVAY safely and effectively. See full prescribing information for BYLVAY. <br/>
      <br/>BYLVAY (odevixibat) capsules, for oral use <br/>BYLVAY (odevixibat) oral pellets <br/>Initial U.S. Approval: 2021</title>
   <effectiveTime value="20250325"/>
   <setId root="0935cd31-3251-4a0a-ac23-25ca4be12be9"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="118461578" root="1.3.6.1.4.1.519.1"/>
            <name>Ipsen Biopharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="915833842" root="1.3.6.1.4.1.519.1"/>
                        <name>Syngene International Limited.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3301" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3302" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3303" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3304" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3301" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3302" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3303" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3304" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="233170864" root="1.3.6.1.4.1.519.1"/>
                        <name>Almac Pharma Services Limited</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3301" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3302" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3303" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3304" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3301" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3302" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3303" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="15054-3304" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="24068310-ecae-437d-ab90-7a66bbbdb289"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250325"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="15054-3301" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Bylvay</name>
                        <formCode code="C42896" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE, COATED PELLETS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>odevixibat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="ug"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2W150K0UUC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>odevixibat</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2W150K0UUC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>odevixibat</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="15054-3301-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240110"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215498" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240110"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>Ivory/White Opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A200</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="15054-3302" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Bylvay</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>odevixibat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="400" unit="ug"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2W150K0UUC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>odevixibat</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2W150K0UUC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>odevixibat</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="15054-3302-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240110"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215498" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240110"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CE">
                              <originalText>Medium Orange Opaque/White Opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A400</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="15054-3303" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Bylvay</name>
                        <formCode code="C42896" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE, COATED PELLETS"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>odevixibat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="600" unit="ug"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2W150K0UUC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>odevixibat</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2W150K0UUC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>odevixibat</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="15054-3303-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240110"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215498" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240110"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE" xsi:type="CE">
                              <originalText>Ivory/White Opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A600</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="15054-3304" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Bylvay</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>odevixibat</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="1200" unit="ug"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="2W150K0UUC" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>odevixibat</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="2W150K0UUC" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>odevixibat</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="30" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="15054-3304-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240110"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215498" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20240110"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORANGE" xsi:type="CE">
                              <originalText>Medium Orange Opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="16" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A1200</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="9a33b02a-63bc-42a4-9801-732746f10415"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table styleCode="Noautorules" width="100%">
                           <col width="80%" align="left" valign="top"/>
                           <col width="20%" align="right" valign="bottom"/>
                           <tbody>
                              <tr>
                                 <td>Contraindications (<linkHtml href="#S4">4</linkHtml>)</td>
                                 <td>03/2025</td>
                              </tr>
                              <tr>
                                 <td>Warnings and Precautions (<linkHtml href="#S5.1">5.1</linkHtml>, <linkHtml href="#S5.3">5.3</linkHtml>)</td>
                                 <td>03/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="722c2426-ec44-4db5-bbe6-416341de3aaa"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: </paragraph>
                        <paragraph>
                           <content styleCode="bold">Progressive Familial Intrahepatic Cholestasis (PFIC)</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitation of Use</content>:</paragraph>
                        <paragraph>BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. (<linkHtml href="#S1.1">1.1</linkHtml>, <linkHtml href="#S12.5">12.5</linkHtml>, <linkHtml href="#S14">14</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">Alagille Syndrome (ALGS)</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="b5a0798b-03a6-494e-a863-dae2b922a02c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1	Progressive Familial Intrahepatic Cholestasis (PFIC)</title>
                     <text>
                        <paragraph>BYLVAY is indicated for the treatment of pruritus in patients 3 months of age and older with PFIC.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="7de5a83f-d5be-4363-ab0f-1e28caf7ae3e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Limitations of Use</content>
                              </paragraph>
                              <list>
                                 <item>BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein <content styleCode="italics">[see <linkHtml href="#S12.5">Clinical Pharmacology (12.5)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                                 </item>
                              </list>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="4d27d38d-d780-4367-9f22-2c4b5f0bbdba"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2	Alagille Syndrome (ALGS)</title>
                     <text>
                        <paragraph>BYLVAY is indicated for the treatment of cholestatic pruritus in patients 12 months of age and older with ALGS.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="a0a54d31-6ed9-432b-96ec-64b4978e2d37"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Recommended Dosage</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">PFIC:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Patients 3 months and older: 40 mcg/kg taken orally once daily. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>If there is no improvement in pruritus after 3 months, the dosage may be increased in 40 mcg/kg increments up to 120 mcg/kg once daily, not to exceed a daily dosage of 6 mg/day. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">ALGS:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Patients 12 months and older: 120 mcg/kg taken orally once daily. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Preparation and Administration Instructions</content>
                           </item>
                        </list>
                        <list listType="unordered" styleCode="disc">
                           <item>Administer BYLVAY in the morning with a meal. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                           <item>Do not crush or chew capsules. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                           <item>See full prescribing information for preparation and administration instructions. (<linkHtml href="#S2.4">2.4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="c7f378e6-1478-48f7-af2e-2209ea032ac9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1	Recommended Dosage for Progressive Familial Intrahepatic Cholestasis (PFIC) in Patients Aged 3 Months and Older</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>The recommended dosage of BYLVAY is 40 mcg/kg taken orally once daily in the morning with a meal. Table 1 below shows the recommended once daily dosage by body weight.</item>
                           <item>If there is no improvement in pruritus after 3 months, the dosage may be increased in 40 mcg/kg increments up to 120 mcg/kg once daily not to exceed a daily dosage of 6 mg/day.</item>
                           <item>BYLVAY oral pellets are intended for use by patients weighing less than 19.5 kilograms.</item>
                           <item>BYLVAY capsules are intended for use by patients weighing 19.5 kilograms or above.</item>
                        </list>
                        <table width="60%">
                           <caption>Table 1. Recommended Dosage for PFIC in Patients aged 3 months and older (40 mcg/kg/day)</caption>
                           <col width="40%" align="center" valign="top"/>
                           <col width="60%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Body Weight (kg)</th>
                                 <th styleCode="Rrule">Once Daily Dosage (mcg)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">7.4 and below</td>
                                 <td styleCode="Rrule">200</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">7.5 to 12.4</td>
                                 <td styleCode="Rrule">400</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">12.5 to 17.4</td>
                                 <td styleCode="Rrule">600</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">17.5 to 25.4</td>
                                 <td styleCode="Rrule">800</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">25.5 to 35.4</td>
                                 <td styleCode="Rrule">1,200</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">35.5 to 45.4</td>
                                 <td styleCode="Rrule">1,600</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">45.5 to 55.4</td>
                                 <td styleCode="Rrule">2,000</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">55.5 and above</td>
                                 <td styleCode="Rrule">2,400</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="c499223b-0508-4c6e-acc8-e7a91e70d30d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2	Recommended Dosage for Alagille Syndrome (ALGS) in Patients Aged 12 Months and Older</title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>The recommended dosage of BYLVAY is 120 mcg/kg taken orally once daily in the morning with a meal. Table 2 below shows the recommended once daily dosage by body weight.</item>
                           <item>BYLVAY oral pellets are intended for use by patients weighing less than 19.5 kilograms.</item>
                           <item>BYLVAY capsules are intended for use by patients weighing 19.5 kilograms or above.</item>
                        </list>
                        <table width="60%">
                           <caption>Table 2. Recommended Dosage for ALGS in Patients aged 12 months and older (120 mcg/kg/day)</caption>
                           <col width="40%" align="center" valign="top"/>
                           <col width="60%" align="center" valign="top"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule">Body Weight (kg)</th>
                                 <th styleCode="Rrule">Once Daily Dosage (mcg)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">7.4 and below</td>
                                 <td styleCode="Rrule">600</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">7.5 to 12.4</td>
                                 <td styleCode="Rrule">1,200</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">12.5 to 17.4</td>
                                 <td styleCode="Rrule">1,800</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">17.5 to 25.4</td>
                                 <td styleCode="Rrule">2,400</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">25.5 to 35.4</td>
                                 <td styleCode="Rrule">3,600</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">35.5 to 45.4</td>
                                 <td styleCode="Rrule">4,800</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">45.5 to 55.4</td>
                                 <td styleCode="Rrule">6,000</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">55.5 and above</td>
                                 <td styleCode="Rrule">7,200</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S2.3">
                     <id root="0bfac377-96c5-4ac3-9c95-6290c9748154"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3	Dosage Modification for Management of Adverse Reactions    </title>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="57d827b9-92fe-4ea5-82c2-2230379e8205"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Tolerability for Alagille Syndrome (ALGS)</content>
                              </paragraph>
                              <paragraph>Dose reduction to 40 mcg/kg/day (Table 1) may be considered if tolerability issues occur in the absence of other causes. Once tolerability issues stabilize, increase to 120 mcg/kg/day.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="373668ab-a079-4e77-8bc1-67e4810a4cb1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Liver Test Abnormalities</content>
                              </paragraph>
                              <paragraph>Establish the baseline pattern of variability of liver tests prior to starting BYLVAY, so that potential signs of liver injury can be identified. Monitor liver tests (e.g., ALT [alanine aminotransferase], AST [aspartate aminotransferase], TB [total bilirubin], DB [direct bilirubin] and International Normalized Ratio [INR]) during treatment with BYLVAY. Interrupt BYLVAY if new onset liver test abnormalities occur or symptoms consistent with clinical hepatitis are observed <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                              </paragraph>
                              <paragraph>Once the liver test abnormalities either return to baseline values or stabilize at a new baseline value, consider restarting BYLVAY at the recommended dosage <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.2">2.2)</linkHtml>]</content>. Consider discontinuing BYLVAY permanently if liver test abnormalities recur.</paragraph>
                              <paragraph>Discontinue BYLVAY permanently if a patient experiences a hepatic decompensation event (e.g., variceal hemorrhage, ascites, hepatic encephalopathy).</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.4">
                     <id root="a29e77f1-eb2d-4b29-ad8c-5e9608636946"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Preparation and Administration Instructions </title>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>For patients taking bile acid binding resins, take BYLVAY at least 4 hours before or 4 hours after taking a bile acid binding resin <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                           </item>
                           <item>Do not crush or chew capsules. <br/>
                              <paragraph>
                                 <content styleCode="bold underline">Oral Pellets:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="circle">
                                 <item>Mix the contents of the shell containing Oral Pellets into soft food or a liquid (as described below).</item>
                                 <item>Discard the emptied shells. Do not let your child swallow the unopened shells containing the Oral Pellets.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="underline">Administration Instructions for patients capable of swallowing soft food:</content>
                              </paragraph>
                              <list listType="ordered" styleCode="arabic">
                                 <item>Administer BYLVAY with the first morning meal.</item>
                                 <item>Place a small amount (up to 2 tablespoons [30 mL]) of soft food (apple sauce, oatmeal, banana or carrot puree, chocolate or rice pudding) in a bowl. Keep the soft food at, or cooler than, room temperature.</item>
                                 <item>Open the shell containing Oral Pellets and empty the contents into the bowl of soft food. Gently tap the Oral Pellet shell to ensure that all contents have been dispersed.</item>
                                 <item>If the dose requires more than one shell of Oral Pellets, repeat Step 3.</item>
                                 <item>Gently mix until well dispersed and administer the entire dose immediately.</item>
                                 <item>Follow the dose with breast milk, infant formula, or other age-appropriate liquid.</item>
                                 <item>Do not store the mixture for future use.</item>
                                 <item>For patients unable to swallow soft food, see <linkHtml href="#Administration">the instructions below</linkHtml>.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="underline" ID="Administration">Administration Instructions with liquids (Using an oral dosing syringe):</content>
                              </paragraph>
                              <list listType="ordered" styleCode="arabic">
                                 <item>Administer BYLVAY with the first morning meal.</item>
                                 <item>Open the shell containing Oral Pellets and empty the contents into a small mixing cup. Gently tap the shell containing Oral Pellets to ensure that all contents have been emptied into the mixing cup.</item>
                                 <item>If the dose requires more than one shell of Oral Pellets, repeat Step 2.</item>
                                 <item>Add 1 teaspoon (5 mL) of an age-appropriate liquid (for example, breast milk, infant formula, or water). 											</item>
                                 <item>Let the pellets sit in the liquid for approximately 5 minutes to allow complete wetting REMINDER: The Oral Pellets will not dissolve in the liquid.</item>
                                 <item>After 5 minutes, place the tip of the oral syringe completely into the mixing cup. Pull the plunger of the syringe up slowly to withdraw the liquid/pellet mixture into the syringe. Gently push the plunger down again to expel the liquid/pellet mixture back into the mixing cup. Do this 2 to 3 times to ensure complete mixing of the pellets into the liquid.</item>
                                 <item>Withdraw the entire contents into the oral syringe by pulling the plunger on the end of the syringe.</item>
                                 <item>Place the tip of the syringe into the front of the patient's mouth between the tongue and the side of the mouth, and then gently push the plunger down to squirt the liquid/pellet mixture between your child's tongue and the side of the mouth. Do not squirt liquid/pellet mixture in the back of the child's throat because this could cause gagging or choking.</item>
                                 <item>Do not administer via a bottle or "sippy cup" because the Oral Pellets will not pass through the opening. The oral pellets will not dissolve in liquid.</item>
                                 <item>Follow the dose with breast milk, infant formula, or other age-appropriate liquid.</item>
                                 <item>If any pellet/liquid mixture remains in the mixing cup, repeat Step 7 and Step 8 until the entire dose has been administered.</item>
                                 <item>Check the child's mouth to make sure all of the liquid/pellet mixture has been swallowed.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold underline">Capsules:</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="underline">Administration Instructions:</content>
                              </paragraph>
                              <list listType="ordered" styleCode="arabic">
                                 <item>Take in the morning with a meal.</item>
                                 <item>Swallow the capsule whole with a glass of water.</item>
                                 <item>Alternatively, for patients unable to swallow the capsules whole, BYLVAY capsules may be opened, and sprinkled and mixed with a small amount of soft food, or mixed with an age-appropriate liquid. Follow directions above for oral pellets to prepare and administer such a mixture.</item>
                              </list>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="12cbdf89-dab9-4d69-bdb5-001f12dc17a9"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <list listType="unordered" styleCode="disc">
                     <item>Oral Pellets: <list listType="unordered" styleCode="disc">
                           <item>200 mcg: capsule with ivory opaque cap and white opaque body; imprinted "A200" (black ink). </item>
                           <item>600 mcg: capsule with ivory opaque cap and body; imprinted "A600" (black ink).</item>
                        </list>
                     </item>
                     <item>Capsules:<list listType="unordered" styleCode="disc">
                           <item>400 mcg: capsule with medium orange opaque cap and white opaque body; imprinted "A400" (black ink). </item>
                           <item>1200 mcg: capsule with medium orange opaque cap and body; imprinted "A1200" (black ink).</item>
                        </list>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Oral Pellets: 200 mcg, 600 mcg (<linkHtml href="#S3">3</linkHtml>)</item>
                           <item>Capsules: 400 mcg, 1200 mcg (<linkHtml href="#S3">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="44701f6d-e95e-4194-8643-1ddb2c103571"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">IBAT inhibitors, including BYLVAY, are contraindicated in patients with prior or active hepatic decompensation events (e.g., variceal hemorrhage, ascites, hepatic encephalopathy) <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with prior or active hepatic decompensation events (e.g., variceal hemorrhage, ascites, hepatic encephalopathy). (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="1bd156f9-3533-401a-ad8d-45e0a2455981"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Hepatoxicity</content>: Obtain baseline liver tests and monitor patients frequently for the first 6 to 8 months after starting therapy, and as clinically indicated thereafter during treatment. If liver test abnormalities or signs of clinical hepatitis occur, consider dose reduction or treatment interruption. For persistent or recurrent liver test abnormalities relative to baseline, discontinue BYLVAY. Monitor patients with compensated cirrhosis or portal hypertension more frequently. Permanently discontinue BYLVAY if hepatic decompensation occurs. (<linkHtml href="#S2.3">2.3</linkHtml>, <linkHtml href="#S5.1">5.1</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Diarrhea</content>: Treat dehydration. Treatment interruption or discontinuation may be required for persistent diarrhea. (<linkHtml href="#S5.2">5.2</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Fat-Soluble Vitamin (FSV) Deficiency</content>: Obtain baseline levels and monitor during treatment. Supplement with FSV if deficiency is observed. If FSV deficiency persists or worsens despite FSV supplementation, consider permanent discontinuation of treatment. Interrupt treatment with BYLVAY if bleeding occurs. Optimize treatment of FSV deficiency and consider restarting BYLVAY once the patient is clinically stable. (<linkHtml href="#S5.3">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="9854220e-d723-42a1-a28c-9502721ce943"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hepatoxicity</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">BYLVAY treatment is associated with a potential for drug-induced liver injury (DILI).</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In the PFIC and ALGS trials, treatment-emergent elevations of liver tests or worsening of liver tests occurred. Of the six patients who experienced DILI, two underwent liver transplant.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Obtain baseline liver tests because some ALGS and PFIC patients have abnormal liver tests at baseline.  Monitor patients frequently for the first 6 to 8 months after starting therapy and as clinically indicated thereafter during treatment with BYLVAY. Monitor for elevation in liver tests, for the development of liver-related adverse reactions, and for physical signs of hepatic decompensation. If liver test abnormalities or signs of clinical hepatitis occur in the absence of other causes, consider dose reduction or treatment interruption.</content>
                        </paragraph>
                        <paragraph>Permanently discontinue BYLVAY if a patient experiences the following:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>persistent or recurrent liver test abnormalities, or</item>
                           <item>upon rechallenge, signs and symptoms consistent with clinical hepatitis, or</item>
                           <item>a hepatic decompensation event.</item>
                        </list>
                        <paragraph>
                           <content styleCode="xmChange">The safety and effectiveness of BYLVAY have not been established in patients with decompensated cirrhosis. Monitor patients with compensated cirrhosis or portal hypertension more frequently and discontinue BYLVAY if hepatic decompensation occurs. IBAT inhibitors, including BYLVAY, are contraindicated in patients with prior or active hepatic decompensation events <content styleCode="italics">[see <linkHtml href="#S4">Contraindications (4)</linkHtml>]</content>.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="42d86625-282e-458d-976b-6ce8af30ee86"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Diarrhea</title>
                     <text>
                        <paragraph>In Trial 1, diarrhea in PFIC patients was reported in 2 (10%) placebo-treated patients, 9 (39%) BYLVAY-treated 40 mcg/kg/day patients and 4 (21%) BYLVAY-treated 120 mcg/kg/day patients. Treatment interruption due to diarrhea occurred in 2 patients with 3 events during treatment with BYLVAY 120 mcg/kg/day. Treatment interruption due to diarrhea ranged between 3 to 7 days <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. One patient treated with BYLVAY 120 mcg/kg/day withdrew from Trial 1 due to persistent diarrhea.</paragraph>
                        <paragraph>In Trial 3, diarrhea in ALGS patients was reported in 1 placebo-treated patient (6%) and in 10 (29%) BYLVAY-treated patients <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>]</content>. No patients interrupted or permanently discontinued BYLVAY due to diarrhea.	</paragraph>
                        <paragraph>If diarrhea occurs, monitor for dehydration and treat promptly. Interrupt BYLVAY dosing if a patient experiences persistent diarrhea. Restart BYLVAY at 40 mcg/kg/day when diarrhea resolves, and increase the dose as tolerated if appropriate. If diarrhea persists and no alternate etiology is identified, stop BYLVAY treatment.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.3">
                     <id root="793ee8d0-157c-4ee2-9f69-489d347a2c43"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3	Fat-Soluble Vitamin Deficiency</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">BYLVAY may adversely affect absorption of fat-soluble vitamins (FSV). FSV include vitamin A, D, E, and K (measured using INR levels). PFIC and ALGS patients can have FSV deficiency at baseline and are frequently supplemented with FSV.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">In Trial 1 in PFIC patients, new onset or worsening of existing FSV deficiency was reported in 1 (5%) placebo-treated patient, and 3 (16%) BYLVAY-treated 120 mcg/kg/day patients; none of the patients treated with BYLVAY dosage 40 mcg/kg/day had new onset or worsening of existing FSV deficiency.</content>
                        </paragraph>
                        <paragraph>In Trial 3 in ALGS patients, new or worsening of existing FSV deficiency was reported in 3 (17.6%) placebo- treated patients and 3 (8.6%) BYLVAY-treated patients <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Obtain serum FSV levels at baseline and monitor during treatment, along with any clinical manifestations of FSV deficiency. If FSV deficiency is diagnosed, supplement with FSV. If FSV deficiency persists or worsens despite adequate FSV supplementation, consider permanent discontinuation of BYLVAY depending on the benefit and risk balance.</paragraph>
                        <paragraph>If complications of FSV deficiency occur, consider interrupting BYLVAY treatment and reassess to ensure adequate supplementation with FSV. Consider restarting BYLVAY once the patient is clinically stable.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="8cbe6ea3-fdaa-43e1-9286-a30835ff8f67"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Bleeding</content>
                              </paragraph>
                              <paragraph>Interrupt treatment with BYLVAY if bleeding occurs. Optimize treatment of FSV deficiency and consider restarting BYLVAY once the patient is clinically stable.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="cba6b6e2-1dc8-483d-97a5-494ac505612e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are discussed in greater detail in other sections of the label: </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Hepatotoxicity [<content styleCode="italics">see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>
                        </content>]</item>
                     <item>Diarrhea <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>]</content>
                     </item>
                     <item>Fat-Soluble Vitamin Deficiency <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="bold">PFIC:</content> Most common adverse reactions (&gt;2%) are liver test abnormalities, diarrhea, abdominal pain, vomiting, and fat-soluble vitamin deficiency. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <paragraph>
                           <content styleCode="bold">ALGS:</content> Most common adverse reactions (&gt;5%) are diarrhea, abdominal pain, hematoma, and decreased weight. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Ipsen Biopharmaceuticals, Inc. at 1-855-463-5127, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="ce0be485-b395-47a4-a26a-15a2c8c87184"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1	Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="78798b0c-0570-4c85-8c7d-b5882e2ac3cf"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">PFIC Clinical Studies</content>
                              </paragraph>
                              <paragraph>Trial 1 is a randomized, double-blind, placebo-controlled, 24-week study of two dose levels of BYLVAY (40 mcg/kg and 120 mcg/kg) administered once daily <content styleCode="italics">[see <linkHtml href="#S14.1">Clinical Studies (14.1)</linkHtml>]</content>. Sixty-two patients were randomized (1:1:1) to receive one of the following:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>BYLVAY 40 mcg/kg/day (n=23), </item>
                                 <item>BYLVAY 120 mcg/kg/day (n=19), or </item>
                                 <item>Placebo (n=20). </item>
                              </list>
                              <paragraph>Table 3 summarizes the frequency of adverse reactions reported in ≥2% and at a rate greater than placebo in patients treated with BYLVAY in Trial 1. The most common adverse reactions observed in Trial 1 included diarrhea, liver test abnormalities, vomiting, abdominal pain, and fat-soluble vitamin deficiency.</paragraph>
                              <table width="75%">
                                 <caption>Table 3. Common Adverse Reactions<footnote>Adverse reactions that occurred in ≥2% of BYLVAY-treated patients</footnote> from a Clinical Study of BYLVAY in Patients with Progressive Familial Intrahepatic Cholestasis (Trial 1) </caption>
                                 <col width="30%" align="left" valign="middle"/>
                                 <col width="20%" align="center" valign="middle"/>
                                 <col width="25%" align="center" valign="middle"/>
                                 <col width="25%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="bottom">Adverse Reaction</th>
                                       <th styleCode="Rrule" valign="bottom">Placebo<br/>N=20<br/>n (%)</th>
                                       <th styleCode="Rrule" valign="bottom">BYLVAY 40 mcg/kg/day<br/>N=23<br/>n (%)</th>
                                       <th styleCode="Rrule" valign="bottom">BYLVAY 120 mcg/kg/day<br/>N=19<br/>n (%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">2 (10%)</td>
                                       <td styleCode="Rrule">9 (39%)</td>
                                       <td styleCode="Rrule">4 (21%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Transaminases increased (ALT, AST)</td>
                                       <td styleCode="Rrule">1 (5%)</td>
                                       <td styleCode="Rrule">3 (13%)</td>
                                       <td styleCode="Rrule">4 (21%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Vomiting</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">4 (17%)</td>
                                       <td styleCode="Rrule">3 (16%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Abdominal pain</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">3 (13%)</td>
                                       <td styleCode="Rrule">3 (16%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Blood bilirubin increased</td>
                                       <td styleCode="Rrule">2 (10%)</td>
                                       <td styleCode="Rrule">3 (13%)</td>
                                       <td styleCode="Rrule">2 (11%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Fat-soluble vitamin deficiency (A, D, E)</td>
                                       <td styleCode="Rrule">1 (5%)</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">3 (16%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Splenomegaly</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2 (11%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Cholelithiasis</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">1 (5%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Dehydration	</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">1 (5%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Fracture</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">1 (4%)</td>
                                       <td styleCode="Rrule">0</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Trial 2 is a 72-week, open-label, single-arm trial in PFIC type 1, 2, and 3 patients. Age of the enrolled patients ranged from 4 months to 26 years. BYLVAY 120 mcg/kg/day was administered once daily. A total of 116 PFIC patients were enrolled, of which 56 patients were rolled over from Trial 1. In addition to patients rolled over from Trial 1, an additional 60 patients were enrolled to Trial 2. Treatment-emergent adverse reactions were similar as observed in Trial 1. Adverse reactions observed in Trial 2 but not described in Trial 1 (Table 3) included increased INR (16%), epistaxis (9%), coagulopathy (3%), iron deficiency anemia (3%), prolonged prothrombin time (2%) and variceal hemorrhage, stoma hemorrhage, hematochezia, and rectal hemorrhage (&lt;1% each). The most common reason for BYLVAY treatment interruption was liver test abnormalities (increases in ALT, AST, direct and total bilirubin).</paragraph>
                              <paragraph>Of the 33 patients who discontinued BYLVAY in Trial 2, five underwent or were referred for liver transplantation and one patient underwent surgical biliary diversion (SBD). There were a total of 19 patients who underwent surgical intervention in Trial 2, with one patient who had SBD followed by liver transplant, 15 patients who underwent liver transplant alone, and three patients who underwent SBD alone.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="49ede363-9f44-450f-9fef-2815eb52f2dc"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="bold">ALGS Clinical Studies</content>
                              </paragraph>
                              <paragraph>Trial 3 is a randomized, double-blind, placebo-controlled, 24-week study of a single dose level of BYLVAY (120 mcg/kg) administered once daily <content styleCode="italics">[see <linkHtml href="#S14.2">Clinical Studies (14.2)</linkHtml>]</content>. Fifty-two patients were randomized (2:1) to receive one of the following:</paragraph>
                              <list listType="unordered" styleCode="disc">
                                 <item>BYLVAY 120 mcg/kg/day (n=35), or </item>
                                 <item>Placebo (n=17). </item>
                              </list>
                              <paragraph>Table 4 summarizes the frequency of adverse reactions in patients with ALGS, reported in ≥5% and at a rate greater than placebo in patients treated with BYLVAY in Trial 3. No patients discontinued study treatment due to an adverse reaction. The most common adverse reactions observed in Trial 3 included diarrhea, abdominal pain, hematoma, and decreased weight.</paragraph>
                              <table width="75%">
                                 <caption>Table 4. Common Adverse Reactions<footnote>Adverse reactions that occurred in ≥5% of BYLVAY-treated patients</footnote> from a Clinical Study of BYLVAY in Patients with Alagille Syndrome (Trial 3) </caption>
                                 <col width="35%" align="left" valign="middle"/>
                                 <col width="30%" align="center" valign="middle"/>
                                 <col width="35%" align="center" valign="middle"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="bottom">Adverse Reaction</th>
                                       <th styleCode="Rrule" valign="bottom">Placebo<br/>N=17<br/>n (%)</th>
                                       <th styleCode="Rrule" valign="bottom">BYLVAY 120 mcg/kg/day<br/>N=35<br/>n (%)</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Diarrhea</td>
                                       <td styleCode="Rrule">1 (6%)</td>
                                       <td styleCode="Rrule">10 (29%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Abdominal Pain</td>
                                       <td styleCode="Rrule">1 (6%)</td>
                                       <td styleCode="Rrule">5 (14%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Hematoma</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">3 (9%)</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Weight decreased</td>
                                       <td styleCode="Rrule">0</td>
                                       <td styleCode="Rrule">2 (6%)</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>Trial 4 is a 72-week, open-label extension study in 49 pediatric patients with ALGS aged 1 to 15 years. BYLVAY 120 mcg/kg/day was administered once daily. Treatment-emergent adverse reactions were similar to those observed in Trial 3. The most common reason for BYLVAY treatment interruption was gastrointestinal disorders, including diarrhea and abdominal pain. </paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="1c7bd349-a14e-4ff3-b1f6-6c9653572fe1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Hepatotoxicity</content>
                              </paragraph>
                              <paragraph>BYLVAY treatment is associated with a potential for DILI.</paragraph>
                              <paragraph>In the PFIC and ALGS trials, treatment-emergent elevations of liver tests or worsening of liver tests occurred. Of the six patients who experienced DILI, two underwent liver transplant.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S6.2">
                     <id root="f93b43c7-4b77-49a1-8ea5-dc92481f6841"/>
                     <code code="90375-7" codeSystem="2.16.840.1.113883.6.1" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>6.2	Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during post-approval use of BYLVAY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal disorders</content>: gastrointestinal hemorrhage, gingival hemorrhage, liver transplant</paragraph>
                        <paragraph>
                           <content styleCode="italics">Investigations</content>: gamma-glutamyltransferase increased, hemoglobin decreased</paragraph>
                        <paragraph>
                           <content styleCode="italics">Nervous system disorders:</content> extra-axial hemorrhage (subdural hemorrhage)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Respiratory, thoracic, and mediastinal disorders:</content> epistaxis</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="1126f550-7f13-4380-9891-1e6d55fc8e61"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="S7.1">
                     <id root="950fef45-fa5e-462a-8b34-d042b3eff5f0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1	Bile Acid Binding Resins</title>
                     <text>
                        <paragraph>Administer bile acid binding resins (e.g., cholestyramine, colesevelam, or colestipol) at least 4 hours before or 4 hours after administration of BYLVAY <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>]</content>. Bile acid binding resins may bind odevixibat in the gut, which may reduce BYLVAY efficacy. </paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="24a5206f-40bd-41eb-8078-5d4e94da9d00"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Pregnancy: Based on animal data, may cause cardiac malformations (<linkHtml href="#S8.1">8.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="7d04f5ce-82ae-4885-ad8e-55f496116811"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="f6221902-33f8-41ee-a449-a1b7164c6d85"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no human data on BYLVAY use in pregnant persons to establish a drug-associated risk of major birth defects, miscarriage, or adverse developmental outcomes. Based on findings from animal reproduction studies, BYLVAY may cause cardiac malformations when a fetus is exposed during pregnancy. In pregnant rabbits treated orally with odevixibat during organogenesis, an increased incidence of malformations in fetal heart, great blood vessels, and other vascular sites occurred at all doses; maternal systemic exposure at the lowest dose was 2.1 times the maximum recommended dose <content styleCode="italics">(see <linkHtml href="#Data">Data</linkHtml>)</content>. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                              <paragraph>There is a pregnancy safety study that monitors pregnancy outcomes in women exposed to BYLVAY during pregnancy. Pregnant women exposed to BYLVAY, or their healthcare providers, should report BYLVAY exposure by calling 1-855-463-5127.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section ID="Data">
                           <id root="66f3d6bd-20df-475e-a63e-c76f4ab7b129"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                           <component>
                              <section>
                                 <id root="23279507-b0bc-40fe-85d5-11b86b020a88"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>In an embryo-fetal development study, pregnant rabbits received oral doses of 10, 30, or 100 mg/kg/day during the period of organogenesis. Fetuses from all maternal groups treated with odevixibat showed an increase in cardiovascular malformations, which included 5-chambered heart, small ventricle, large atrium, ventricular septum defect, misshapen aortic valve, dilated aortic arch, right sided and retroesophageal aortic arch, fusion of aortic arch and pulmonary trunk, ductus arteriosus atresia, and absence of subclavian artery. These malformations occurred at 2.1 times the maximum recommended dose and higher, based on AUC (area under the plasma concentration-time curve). Odevixibat was shown to cross the placenta in pregnant rats. </paragraph>
                                    <paragraph>No adverse effects on embryo-fetal development were observed following oral administration of 100, 300, or 1,000 mg/kg/day in pregnant rats during organogenesis. An increase in skeletal variations (delayed/incomplete ossification and thick ribs) was observed at 1,000 mg/kg/day. Maternal systemic exposure to odevixibat at the maximum dose tested was 272 times the maximum recommended dose, based on AUC.</paragraph>
                                    <paragraph>No adverse effects on postnatal development were observed in a pre- and postnatal development study, in which female rats were treated orally with up to 1,000 mg/kg/day during organogenesis through lactation. The maternal AUC for odevixibat at 1,000 mg/kg/day was 434 times the maximum recommended dose, based on AUC.</paragraph>
                                 </text>
                                 <effectiveTime value="20250325"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="47c5e92f-7634-4802-b0b3-e8bb8fd61b08"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="336329e3-47b8-4dc0-b51a-63be4d2f464e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>Odevixibat has low absorption following oral administration, and breastfeeding is not expected to result in exposure of the infant to BYLVAY at the recommended doses <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].</content> There are no data on the presence of odevixibat in human milk, the effects on the breastfed infant, or the effects on milk production. BYLVAY may reduce absorption of fat-soluble vitamins <content styleCode="italics">[see <linkHtml href="#S5.3">Warning and Precautions (5.3)</linkHtml>]</content>. Monitor FSV levels and increase FSV intake, if FSV deficiency is observed during lactation. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for BYLVAY and any potential adverse effects on the breastfed child from BYLVAY or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="7ba7cb03-60b9-461b-a226-14fd742d531c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of BYLVAY have been established in pediatric patients 3 months to 17 years of age for the treatment of pruritus in PFIC. Use of BYLVAY in this age group is supported by evidence from one randomized, double-blind, placebo-controlled trial conducted in 62 patients with a confirmed diagnosis of PFIC type 1 or type 2 (Trial 1), and an open-label extension trial in PFIC patients (Trial 2) <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of BYLVAY for the treatment of pruritus in PFIC in pediatric patients less than 3 months of age have not been established.</paragraph>
                        <paragraph>The safety and effectiveness of BYLVAY have been established in pediatric patients 12 months to 17 years of age for the treatment of pruritus in ALGS. Use of BYLVAY in this age group is supported by evidence from one randomized, double-blind, placebo-controlled trial conducted in 52 patients with a confirmed diagnosis of ALGS (Trial 3) and one open-label extension trial in ALGS patients (Trial 4) <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>.</paragraph>
                        <paragraph>The safety and effectiveness of BYLVAY for the treatment of pruritus in ALGS in pediatric patients less than 12 months of age have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="4559f9d8-4bdd-45b8-b035-6c9813136b7a"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>PFIC and ALGS are largely diseases of pediatric and young adult patients. Clinical studies in BYLVAY did not include patients 65 years of age and older.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="7d3651cf-e767-4973-95c9-8aa5c99486f3"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>Patients with PFIC and ALGS may have impaired hepatic function. The efficacy and safety of BYLVAY in PFIC and ALGS patients with clinically significant portal hypertension, and in patients with decompensated cirrhosis have not been established <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>, <linkHtml href="#S4">Contraindications (4)</linkHtml>, <linkHtml href="#S5.1">Warning and Precautions (5.1)</linkHtml>, and <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="e8e89dc8-f03a-4e3b-8ec1-75b63dd5245f"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>The active ingredient in BYLVAY (odevixibat) capsules and BYLVAY (odevixibat) oral pellets, an ileal bile acid transporter (IBAT) inhibitor, is (2S)-2-{[(2R)-2-(2-{[3,3-dibutyl-7-(methylsulfanyl)-1,1-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1λ<sup>6</sup>,2,5-benzothiadiazepin-8yl]oxy}acetamido)-2-(4-hydroxyphenyl)acetly]amino}butanoic acid, which is formulated as the sesquihydrate having the following chemical structure: </paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>The molecular formula is C<sub>37</sub>H<sub>48</sub>N<sub>4</sub>O<sub>8</sub>S<sub>2</sub> × 1.5 H<sub>2</sub>O, with a molecular weight of 768.0 g/mol (anhydrous 740.9 g/mol). Odevixibat sesquihydrate is a white to off-white solid. Its solubility in aqueous solutions is pH-dependent and increases with increased pH. </paragraph>
                  <paragraph>BYLVAY is available for oral administration as oral pellets containing odevixibat sesquihydrate equivalent to 200 mcg or 600 mcg of odevixibat, and as capsules containing odevixibat sesquihydrate equivalent to 400 mcg or 1200 mcg of odevixibat, and the following excipients: hypromellose and microcrystalline cellulose. </paragraph>
                  <paragraph>The capsule shells for the oral pellets contain hypromellose, titanium dioxide and yellow iron oxide.</paragraph>
                  <paragraph>The capsule shells for the capsules contain hypromellose, red iron oxide, titanium dioxide and yellow iron oxide. </paragraph>
                  <paragraph>The imprinting ink contains ferrosoferric oxide/black iron oxide and shellac glaze.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="c27bfdae-cdbd-4619-88d5-afec83886905"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="S12.1">
                     <id root="53f6b115-dd94-4a15-a604-473572ce82c2"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Odevixibat is a reversible inhibitor of the ileal bile acid transporter (IBAT). It decreases the reabsorption of bile acids (primarily the salt forms) from the terminal ileum<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>Pruritus is a common symptom in patients with PFIC and ALGS; the pathophysiology of pruritus in patients with PFIC is not completely understood. Although the complete mechanism by which odevixibat improves pruritus in both PFIC and ALGS patients is unknown, it may involve inhibition of the IBAT, which results in decreased reuptake of bile salts, as observed by a decrease in serum bile acids <content styleCode="italics">[see <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="bf302726-a49f-4208-aa40-889408bd685b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Odevixibat reduces serum bile acids in patients with PFIC and ALGS<content styleCode="italics">.</content>
                        </paragraph>
                        <paragraph>In Trial 1, a 24-week, randomized, double-blind, placebo-controlled trial conducted in 62 patients with a confirmed diagnosis of PFIC type 1 or type 2, the majority of patients (88.7%) had elevated serum bile acids above 100 mcmol/L at baseline <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. Serum bile acids concentrations were reduced from baseline within 4-8 weeks of odevixibat treatment compared to placebo treatment. The decreased concentrations of serum bile acids fluctuated over time but generally were maintained during the treatment over 24 weeks. The extent of decrease in serum bile acids was similar between 40 and 120 mcg/kg.</paragraph>
                        <paragraph>Trial 3 is a 24-week, randomized, double-blind, placebo-controlled trial conducted in 52 patients with a confirmed diagnosis of ALGS who were administered treatment with BYLVAY 120 mcg/kg once daily <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>].</content> At baseline, serum bile acids were variable ranging from 93 to 510 mcmol/L. Serum bile acid concentrations were reduced from baseline as early as Week 4 of odevixibat treatment and the reduction was generally maintained during treatment over 24 weeks. </paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="65497f76-9f81-470b-a7c0-ca24e9c24220"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>In pediatric patients with PFIC, 6 months to 17 years of age who received BYLVAY 40 mcg/kg or 120 mcg/kg once daily with food in the morning, the measurable odevixibat concentrations ranged from 0.06 to 0.72 ng/mL, and odevixibat concentrations were below the limit of quantification (0.05 ng/mL) in the majority of plasma samples.</paragraph>
                        <paragraph>In pediatric patients with ALGS who received BYLVAY 120 mcg/kg once daily with food in the morning, the measurable odevixibat concentrations ranged from 0.05 to 3.4 ng/mL.</paragraph>
                        <paragraph>Following single and repeated oral administration of odevixibat from 0.1 to 3 mg in healthy adults, plasma concentrations of odevixibat were mostly below the limit of quantification (0.05 ng/mL); therefore, AUC and peak plasma concentration (C<sub>max</sub>) could not be calculated. </paragraph>
                        <paragraph>Following a single administration of odevixibat 7.2 mg in healthy adults, the mean (%CV) C<sub>max</sub> and AUC<sub>0-24h</sub> were 0.47 ng/mL (34.8) and 2.19 ng∙h/mL (36.2), respectively. No accumulation of odevixibat was observed following once-daily dosing.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="20aed5b4-96db-4ad3-b3fa-af5780e9be97"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Absorption</content>
                              </paragraph>
                              <paragraph>Odevixibat is minimally absorbed following oral administration. Following a single administration of odevixibat 7.2 mg in healthy adults, odevixibat C<sub>max</sub> is reached between 1 to 5 hours.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                           <component>
                              <section>
                                 <id root="7f6a3049-eee4-4b3f-97e9-33a4629e3ac5"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Sprinkle on Applesauce</content>
                                    </paragraph>
                                    <paragraph>When odevixibat 9.6 mg was administered after sprinkling the pellets on applesauce, decreases of 39% and 35% in C<sub>max</sub> and AUC<sub>0-24h</sub>, respectively, and delayed median T<sub>max</sub> from 3 hours to 4.5 hours were observed compared to administration of whole capsules (eight 1200 mcg capsules) under fasted conditions. The effect of sprinkling on soft food on systemic exposure is not clinically significant <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250325"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="be588807-5528-4dfa-8695-d631808f3c4b"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Food</content>
                                    </paragraph>
                                    <paragraph>Concomitant administration of a high-fat meal (800-1000 calories with approximately 50% of total caloric content of the meal from fat) with a single dose of odevixibat 9.6 mg delayed median T<sub>max</sub> from 3 hours to 4.5 hours and resulted in decreases of 72% and 62% in C<sub>max</sub> and AUC<sub>0-24h</sub>, respectively, compared to administration under fasted conditions in healthy adults. The effect of food on the changes of systemic exposures to odevixibat is not clinically significant <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml>].</content>
                                    </paragraph>
                                 </text>
                                 <effectiveTime value="20250325"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="29766a18-8dd9-46df-97c0-ed9c19349f8e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Distribution</content>
                              </paragraph>
                              <paragraph>Human plasma protein binding of odevixibat is greater than 99% in vitro.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f99ae1f0-8188-4b99-aa7c-066ab9b3db4c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Elimination</content>
                              </paragraph>
                              <paragraph>Following a single oral dose of 7.2 mg odevixibat in healthy adults, the mean half-life (t<sub>1/2</sub>) was 2.36 hours.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                           <component>
                              <section>
                                 <id root="d0bf28a7-0a97-474d-b6ef-0017eae89d20"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Metabolism</content>
                                    </paragraph>
                                    <paragraph>In vitro, odevixibat was metabolized via mono-hydroxylation.</paragraph>
                                 </text>
                                 <effectiveTime value="20250325"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="dc865235-0acd-42c6-bd27-083ad2d65ba0"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Excretion</content>
                                    </paragraph>
                                    <paragraph>Following a single radiolabeled odevixibat 3 mg oral dose in healthy adults, 82.9% of the dose was recovered in feces (97% unchanged) and less than 0.002% in the urine.</paragraph>
                                 </text>
                                 <effectiveTime value="20250325"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="eacd9e8a-d1c1-4d38-93ea-b54ed3cc9182"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                           <component>
                              <section>
                                 <id root="178704bf-2e3a-4b75-9c30-9f2d4442eac4"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Other Drugs on Odevixibat</content>
                                    </paragraph>
                                    <paragraph>Odevixibat is a substrate of P-glycoprotein (P-gp) but not a substrate of breast cancer resistance protein (BCRP). </paragraph>
                                    <paragraph>Coadministration of itraconazole (a strong P-gp inhibitor) with a single dose of BYLVAY 7.2 mg increased odevixibat AUC<sub>0-24h</sub> by 66% and C<sub>max</sub> by 52%, which is not expected to have a clinically significant effect.</paragraph>
                                 </text>
                                 <effectiveTime value="20250325"/>
                              </section>
                           </component>
                           <component>
                              <section>
                                 <id root="95e81998-868a-4522-8f30-f62bb1570d38"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Effect of Odevixibat on Other Drugs</content>
                                    </paragraph>
                                    <paragraph>In in vitro studies, odevixibat was not an inhibitor of CYP isoforms 1A2, 2B6, 2C8, 2C9, 2C19, or 2D6 nor an inducer of CYP isoforms 1A2, 2B6, or 3A4.</paragraph>
                                    <paragraph>Concomitant use of BYLVAY 7.2 mg once daily for 4 days with oral midazolam (a CYP3A4 substrate) in healthy adults decreased the AUC<sub>0-24h</sub> of midazolam and 1-OH midazolam by 29% and 13%, respectively, which is not expected to have a clinically relevant effect.</paragraph>
                                    <paragraph>In in vitro studies, odevixibat did not inhibit the transporters P-gp; BCRP; organic anion transporter polypeptide 1B1 and 1B3(OATP1B1 and OATP1B3); organic anion transporter (OAT)1, OAT3; organic cation transporter 2 (OCT2), multidrug and toxin extrusion transporter 1 and 2K (MATE1 and MATE2K).</paragraph>
                                 </text>
                                 <effectiveTime value="20250325"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.5">
                     <id root="58bb5c90-35ec-4bec-87a0-93e79934de02"/>
                     <code code="66106-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOGENOMICS SECTION"/>
                     <title>12.5 Pharmacogenomics</title>
                     <text>
                        <paragraph>PFIC is a heterogenous disease caused by homozygous or compound heterozygous variants, with different PFIC subtypes occurring in the general population. PFIC2 is the most common subtype accounting for 37-90% of PFIC patients. PFIC1 is caused by variants in the aminophospholipid flippase (ATP8B1) gene, which encodes the Familial Intrahepatic Cholestasis 1 (FIC1) protein, while PFIC2 results from variants in the ABCB11 gene, which encodes the Bile Salt Export Pump (BSEP) protein. PFIC2 patients are further categorized into BSEP subgroups based on their specific variants. The BSEP-1 subgroup includes patients with at least one p.D482G (c.1445A&gt;G) or p.E297G (c.890A&gt;G) variant, BSEP-2 includes patients with at least one missense variant other than p.D482G or p.E297G (non BSEP-1), and BSEP-3 includes patients with variants that are predicted to encode a non-functional protein. No BSEP-3 patients were studied in clinical Trial 1 (NCT03566238). The prevalence of BSEP-1, BSEP-2, and BSEP-3 subgroups are approximately 27.3%, 51.5%, and 21.2%, respectively, based on data from a global consortium characterizing the natural history of severe BSEP deficiency.   </paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="64dc7dd4-d2ef-46b9-bbae-0ecf1dfb97ab"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="S13.1">
                     <id root="6b7417e4-5916-4675-b2af-18dc51f96e47"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="deb952b3-e961-494f-8226-c547494c2124"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>In 2-year carcinogenicity studies, odevixibat was not tumorigenic in rats or mice at oral doses up to 100 mg/kg/day. Systemic exposure to odevixibat (AUC) at the maximum dose studied in rats and mice was approximately 231 and 459 times the maximum recommended dose, respectively.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="78e58d79-0424-4da5-bcd7-541e1232914c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Odevixibat was negative in the in vitro bacterial reverse mutation (Ames) assay, the in vitro mouse lymphoma cell gene mutation assay, and the in vivo rat micronucleus test.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="ab36776a-29d6-4658-8e2d-7aceb3aee200"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Odevixibat had no effects on fertility or reproductive function in male and female rats at oral doses of up to 1,000 mg/kg/day.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="1ef74c85-c645-45ef-8618-d3cbf58abaf6"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="S14.1">
                     <id root="32806fd6-a9b9-48dd-b964-ca03f23dc5c4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1	PFIC</title>
                     <text>
                        <paragraph>The efficacy of BYLVAY was evaluated in Trial 1 (NCT03566238), a 24-week, randomized, double-blind, placebo-controlled trial. Trial 1 was conducted in 62 pediatric patients, aged 6 months to 17 years, with a confirmed molecular diagnosis of PFIC type 1 or type 2, and presence of pruritus at baseline. Patients with variants in the ABCB11 gene that predict non-function or complete absence of the bile salt export pump (BSEP) protein, who had experienced prior hepatic decompensation events, who had other concomitant liver disease, whose INR was greater than 1.4, whose ALT or total bilirubin was greater than 10-times the upper limit of normal (ULN), or who had received a liver transplant were excluded in Trial 1.</paragraph>
                        <paragraph>Patients were randomized to placebo (n=20), 40 mcg/kg (n=23), or 120 mcg/kg (n=19). Study drug was administered once daily with a meal in the morning. In patients weighing less than 19.5 kg or patients who could not swallow the whole capsule, study drug was sprinkled on soft food and then administered orally.</paragraph>
                        <paragraph>Median age (range) of the patients in Trial 1 was 3.2 (0.5 to 15.9) years; 3 patients were older than 12 years of age. Of the 62 patients, 50% were male and 84% were white; 27% had PFIC type 1, and 73% had PFIC type 2. The mean (standard error [SE]) scratching score in the 2 weeks prior to baseline was 2.9 (0.08). Baseline mean (SE) eGFR was 164 (30.6) mL/min/1.73 m<sup>2</sup>. Baseline median (range) ALT, AST, and total bilirubin were 65 (16-798) U/L, 83.5 (32-405) U/L, and 2.2 (0.2-18.6) mg/dL, respectively.</paragraph>
                        <paragraph>In Trial 1, a total of 13 patients discontinued from trial prematurely either due to no improvement in pruritus (n=11) or due to adverse reactions (n=2); 5/20 (25%) patients discontinued from the placebo arm and 8/42 (19%) patients discontinued from the BYLVAY arms. A total of 11 of the 13 patients rolled over to Trial 2 to receive BYLVAY 120 mcg/kg/day. One patient treated with BYLVAY 120 mcg/kg/day withdrew from the trial due to a treatment-emergent adverse reaction of diarrhea <content styleCode="italics">[see <linkHtml href="#S6">Adverse Reactions (6)</linkHtml>].</content>
                        </paragraph>
                        <paragraph>Given the patients' young age, a single-item observer-reported outcome (ObsRO) was used to measure patients' scratching severity as observed by their caregiver twice daily (once in the morning and once in the evening). Scratching severity was assessed on a 5-point ordinal response scale, with scores ranging from 0 (no scratching) to 4 (worst possible scratching). Patients were included in Trial 1 if their average scratching score was greater than or equal to 2 (medium scratching) in the 2 weeks prior to baseline.</paragraph>
                        <paragraph>Table 5 presents the results of the comparison between BYLVAY and placebo on the mean of patients' percentage of ObsRO assessments over the 24-week treatment period that were scored as 0 (no scratching) or 1 (a little scratching). Patients treated with BYLVAY demonstrated greater improvement in pruritus compared with placebo. Figure 1 displays the mean of patients' worst weekly average scratching scores in each treatment group for each month, where the weekly average utilized the worst score from each day (morning or evening score).</paragraph>
                        <table width="75%">
                           <caption>Table 5: Efficacy Results Over the 24-Week Treatment Period in Patients with PFIC Type 1 or 2 in Trial 1</caption>
                           <col width="25%" align="left" valign="middle"/>
                           <col width="25%" align="center" valign="middle"/>
                           <col width="25%" align="center" valign="middle"/>
                           <col width="25%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule" rowspan="2" valign="bottom">Placebo<br/>(n=20)</th>
                                 <th styleCode="Rrule Botrule" colspan="2">BYLVAY</th>
                              </tr>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule">40 mcg/kg/day<br/>(n=23)</th>
                                 <th styleCode="Rrule">120 mcg/kg/day<br/>(n=19)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="4">
                                    <content styleCode="bold">Mean<footnote>Based on least squares means from analysis of covariance model with daytime and nighttime baseline pruritus scores as covariates and treatment group and stratification factors (i.e., PFIC type and age category) as fixed effects.</footnote> Percentage of Assessments Over the Treatment Period Scored as 0 (No Scratching) or 1 (A Little Scratching) (%)</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Mean (SE)</td>
                                 <td styleCode="Rrule">13.2 (8.7)</td>
                                 <td styleCode="Rrule">35.4 (8.1)</td>
                                 <td styleCode="Rrule">30.1 (9.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean Difference vs Placebo (95% CI)</td>
                                 <td styleCode="Rrule"/>
                                 <td styleCode="Rrule">22.2 (4.7, 39.6)</td>
                                 <td styleCode="Rrule">16.9 (-2.0, 35.7)</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%" styleCode="Noautorules">
                           <col width="100%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td align="center">
                                    <content styleCode="bold">Figure 1: Mean<footnote>Figure 1 presents least squares means<br/>Based on a mixed model repeated measure (MMRM) analysis accounting for baseline score, treatment group, time (in months), treatment-by-baseline interaction, treatment-by-time interaction, and stratification factors (i.e., PFIC type and age category). Missing data were accounted for using placebo-reference multiple imputation.</footnote> of the Worst Weekly Average Scratching Scores for Each Month in Trial 1</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <paragraph>
                                       <renderMultiMedia referencedObject="MM2"/>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <observationMedia ID="MM2">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="bylvay-02.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="b5d7d082-62b9-4183-bb63-5b8355e939ee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2	ALGS</title>
                     <text>
                        <paragraph>The efficacy of BYLVAY was evaluated in Trial 3 (NCT04674761), a 24-week, randomized, double-blind, placebo-controlled trial. Trial 3 was conducted in 52 pediatric patients, aged 6 months to 15 years, with a confirmed diagnosis of ALGS and presence of pruritus at baseline. Patients who had decompensated liver disease, who had other concomitant liver disease, whose INR was greater than 1.4, whose ALT was greater than 10-times the upper limit of normal (ULN) at screening, whose total bilirubin was greater than 15-times the ULN at screening, or who had received a liver transplant were excluded from Trial 3.</paragraph>
                        <paragraph>Patients were randomized to placebo (n=17) or 120 mcg/kg (n=35). Study drug was administered once daily with a meal in the morning. In patients weighing less than 19.5 kg or patients who could not swallow the whole capsule, study drug was sprinkled on soft food and then administered orally. </paragraph>
                        <paragraph>Median age (range) of the patients in Trial 3 was 6.1 (1.7 to 15.5) years in the BYLVAY group and 4.2 (0.5 to 14.3) years in the placebo group; 5 patients were older than 12 years of age. Of the 52 patients, 52% were male and 83% were white; 92% of patients had the JAG1 mutation and 8% had the NOTCH2 mutation. The mean (standard deviation [SD]) scratching score in the 2 weeks prior to baseline was 2.9 (0.6). Baseline mean (SD) eGFR was 159 (51.4) mL/min/1.73 m<sup>2</sup>. Baseline median (range) ALT, AST, and total bilirubin were 152 (39-403) U/L, 135 (57-427) U/L, and 2.0 (0.4-11.4) mg/dL, respectively. </paragraph>
                        <paragraph>Given the patients' young ages, a single-item observer-reported outcome (ObsRO) was used to measure patients' scratching severity as observed by their caregiver twice daily (once in the morning and once in the evening). Scratching severity was assessed on a 5-point ordinal response scale, with scores ranging from 0 (no scratching) to 4 (worst possible scratching). Patients were included in Trial 3 if the average scratching score was greater than or equal to 2 (medium scratching) in the 14 days prior to baseline.</paragraph>
                        <paragraph>Table 6 presents the results of the comparison between BYLVAY and placebo on the change from baseline in average scratching score based on ObsRO assessments to Month 6 (Weeks 21 to 24). The average scratching score for each patient for each month post-baseline was calculated by: (Step 1) averaging the morning scores and averaging the evening scores within a week; (Step 2) averaging the morning and evening weekly scores to yield a single weekly score; and finally (Step 3) averaging the 4 weekly scores within the month. The baseline average scratching score for each patient was calculated by averaging the weekly scores obtained in Step 2 across the 2 weeks prior to randomization and initiation of blinded treatment. Patients treated with BYLVAY demonstrated greater improvement in pruritus compared with placebo. Figure 2 displays the means (95% confidence interval) of patients' average scratching scores in each treatment group for each month.</paragraph>
                        <table width="75%">
                           <caption>Table 6: Efficacy Results in Patients with ALGS in Trial 3</caption>
                           <col width="40%" align="left" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <col width="30%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule"/>
                                 <th styleCode="Rrule" valign="bottom">Placebo<br/>(n=17)</th>
                                 <th styleCode="Rrule" valign="bottom">BYLVAY<br/>120 mcg/kg/day<br/>(n=35)</th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Baseline Average Scratching Score</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Mean (SD)</td>
                                 <td styleCode="Rrule">3.0 (0.6)</td>
                                 <td styleCode="Rrule">2.8 (0.5)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Change from Baseline in Average Scratching Score to Month 6 (Weeks 21 to 24)<footnote>Based on least square means from a mixed-effect model for repeated measures (MMRM) for change from baseline to each month accounting for baseline average scratching score, baseline age stratification (&lt;10, ≥10 years), baseline direct bilirubin, treatment group, time (in months), and treatment-by-time interaction.</footnote>
                                    </content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Mean (SE)</td>
                                 <td styleCode="Rrule">-0.8 (0.2)</td>
                                 <td styleCode="Rrule">-1.7 (0.2)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">Mean Difference vs Placebo (95% CI)<br/>p-value	</td>
                                 <td styleCode="Rrule" colspan="2">-0.9 (-1.4, -0.3)<br/>0.002</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%" styleCode="Noautorules">
                           <col width="100%" align="left" valign="top"/>
                           <tbody>
                              <tr>
                                 <td align="center">
                                    <content styleCode="bold">Figure 2: Mean<footnote>Figure 2 presents means for baseline and least squares means for Month 1 to 6<br/>Least squares means are based on a mixed model repeated measure (MMRM) analysis accounting for baseline average scratching score, baseline age stratification (&lt;10, ≥10 years), baseline direct bilirubin, treatment group, time (in months), and treatment-by-time interaction.</footnote> of the Average Scratching Scores for Each Month in Trial 3</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM3"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <observationMedia ID="MM3">
                           <text>Figure 2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="bylvay-03.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="9abc6cc3-2ebe-4d07-88f2-926d06bc8e16"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section>
                     <id root="c0535a12-64de-4efe-b14c-558355069a89"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold underline">Oral Pellets</content>
                        </paragraph>
                        <list>
                           <item>
                              <caption> </caption>200 mcg Oral Pellets: supplied as Size 0 capsule with ivory opaque cap and white opaque body; imprinted "A200" (black ink). Supplied in bottles of 30 with child-resistant closure (NDC 15054-3301-1).</item>
                           <item>
                              <caption> </caption>600 mcg Oral Pellets: supplied as Size 0 capsule with ivory opaque cap and body; imprinted "A600" (black ink). Supplied in bottles of 30 with child-resistant closure (NDC 15054-3303-1).</item>
                        </list>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="220bed92-e4e9-48df-b473-883fd382b712"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold underline">Capsules</content>
                        </paragraph>
                        <list>
                           <item>
                              <caption> </caption>400 mcg Capsule: supplied as Size 3 capsule with medium orange opaque cap and white opaque body; imprinted "A400" (black ink). Supplied in bottles of 30 with child-resistant closure (NDC 15054-3302-1).</item>
                           <item>
                              <caption> </caption>1,200 mcg Capsule: supplied as Size 3 capsule with medium orange opaque cap and body; imprinted "A1200" (black ink). Supplied in bottles of 30 with child-resistant closure (NDC 15054-3304-1).</item>
                        </list>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="c57cfb62-37a0-4fad-9691-d2639d545ff2"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Storage and Handling:</content>
                        </paragraph>
                        <paragraph>Store at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (between 59°F and 86°F) [See USP Controlled Room Temperature].</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="48c680eb-1cb7-49b0-9280-c2f3f26bb75c"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (Instructions for Use). </paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <section>
                     <id root="1a4e3fa9-6073-41d5-8f1f-6d43c7320674"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Administration Instructions</content>
                        </paragraph>
                        <paragraph>Advise patients or their caregivers(s) to: </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Take BYLVAY in the morning with a meal. Do not swallow the 200 mcg or 600 mcg capsule(s) containing Oral Pellets whole. These are intended to be opened and the contents mixed into soft food or liquids <content styleCode="italics">[see <linkHtml href="#S2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#S2.2">2.2</linkHtml>, <linkHtml href="#S2.4">2.4)</linkHtml>]</content>.</item>
                           <item>Follow stepwise administration Instructions <content styleCode="italics">[see <linkHtml href="#S2.4">Dosage and Administration (2.4)</linkHtml>]</content> for Oral Pellets and Capsules for patients unable to swallow the capsules whole.</item>
                           <item>Take BYLVAY at least 4 hours before or 4 hours after taking a bile acid binding resin (e.g., cholestyramine, colesevelam, or colestipol) <content styleCode="italics">[see <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>].</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="cdd2869b-0938-4bb5-b8b2-c95b57caa490"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Hepatotoxicity</content>
                        </paragraph>
                        <paragraph>Advise patients or their caregiver(s) that liver tests should be obtained before starting BYLVAY and periodically during BYLVAY therapy. Inform patients or their caregiver(s) of the potential risk of hepatotoxicity, and that they will need to undergo monitoring for liver injury. Instruct patients or their caregiver(s) to immediately report any signs or symptoms of severe liver injury to their healthcare provider <content styleCode="italics">[see <linkHtml href="#S2.3">Dosage and Administration (2.3)</linkHtml> and <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2a0a40f1-de74-4731-bffb-a727d67c67c1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Diarrhea</content>
                        </paragraph>
                        <paragraph>Advise patients or their caregiver(s) to notify their healthcare provider if they experience new onset or worsening of diarrhea <content styleCode="italics">[see <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="aec621f0-0a38-4397-8554-7bb0d468e49b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Fat Soluble Vitamin (FSV) Deficiency</content>
                        </paragraph>
                        <paragraph>Advise patients or their caregiver(s) that INR (for vitamin K) and serum levels of vitamins A, D, E will be obtained before starting and periodically during treatment to assess for FSV deficiency <content styleCode="italics">[see <linkHtml href="#S5.3">Warnings and Precautions (5.3)</linkHtml>].</content> Inform patients or their caregiver(s) that they may bleed more easily or may bleed longer. Advise patients or their caregiver(s) to call their healthcare provider for any signs or symptoms of bleeding.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="947fd3c4-7de2-4ca1-997e-a09169a4ed63"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Advise patients or their caregiver(s) that there is a pregnancy safety study that collects pregnancy outcome data in women taking BYLVAY during pregnancy. Pregnant women exposed to BYLVAY, or their healthcare providers, should report BYLVAY exposure by calling 1-855-463-5127 <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="db4d83a2-912f-4559-914c-c6908a5d3662"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for:</paragraph>
                  <paragraph>Ipsen Biopharmaceuticals, Inc.<br/>One Main Street <br/>Cambridge, MA 02142</paragraph>
                  <paragraph>© 2025 Ipsen Biopharmaceuticals, Inc. All rights reserved.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
            </section>
         </component>
         <component>
            <section ID="IFU">
               <id root="bdcf88e0-f4f8-42bb-be79-126ec9b108a1"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Instructions For Use<br/>BYLVAY [bil-vay] <br/>(odevixibat)<br/>Capsules, for oral use<br/>Oral Pellets</title>
               <text>
                  <paragraph>This Instructions for Use contains information on how to give BYLVAY Capsules and Oral Pellets. This information does not take the place of talking to your healthcare provider about your child's medical condition or their treatment.</paragraph>
                  <paragraph>
                     <content styleCode="bold">	Important information you need to know before giving or taking BYLVAY </content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Give BYLVAY <content styleCode="bold">along with the morning meal</content>. </item>
                     <item>Mix BYLVAY in a small amount of soft food (up to 2 tablespoons [30 mL]), such as apple sauce, oatmeal, banana or carrot puree, chocolate or rice pudding, in a bowl. You may also mix BYLVAY with an age-appropriate liquid and give through an oral syringe. </item>
                     <item>If your child is taking bile acid binding resins (for example, cholestyramine, colestipol), give them BYLVAY at least 4 hours before or 4 hours after they take the bile acid binding resin.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Preparing to Give BYLVAY</content>
                  </paragraph>
                  <paragraph>You will be provided with the number of BYLVAY Capsules or Oral Pellets prescribed by your child's healthcare provider in a child-resistant closure.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Giving BYLVAY Oral Pellets with soft food:</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>The shell containing Oral Pellets are to be opened and sprinkled. <content styleCode="bold">Do not</content> let your child swallow the shell containing the Oral Pellets. Dispose of (throw away) the emptied shell.</item>
                     <item>Mix the contents of the Oral Pellets with soft food as shown in <content styleCode="bold">Steps 1 through 9</content> below.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="8%" align="left" valign="top"/>
                     <col width="92%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 1.</content>
                           </td>
                           <td>Give  BYLVAY with the first morning meal. Place a small amount of soft food (up to 2 tablespoons [30 mL], such as apple sauce, oatmeal, banana or carrot puree, chocolate or rice pudding) in a bowl. Keep the soft food at, or cooler than, room temperature. <br/>Note: This small amount of soft food should be less than what your child would normally eat.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 2.</content>
                           </td>
                           <td>Hold the shell containing Oral Pellets horizontally on both ends, twist in opposite directions and pull apart (see <content styleCode="bold">
                                 <linkHtml href="#FigA">Figure A</linkHtml>
                              </content>).</td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2">
                              <renderMultiMedia referencedObject="MM4" ID="FigA"/>
                              <br/>
                              <content styleCode="bold">Figure A</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 3.</content>
                           </td>
                           <td>Empty the Oral Pellets into the bowl of soft food (see <content styleCode="bold">
                                 <linkHtml href="#FigB">Figure B</linkHtml>
                              </content>).</td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2">
                              <renderMultiMedia referencedObject="MM5" ID="FigB"/>
                              <br/>
                              <content styleCode="bold">Figure B</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 4.</content>
                           </td>
                           <td>Gently tap the shell containing Oral Pellets to make sure that all pellets come out (see <content styleCode="bold">
                                 <linkHtml href="#FigC">Figure C</linkHtml>
                              </content>).</td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2">
                              <renderMultiMedia referencedObject="MM6" ID="FigC"/>
                              <br/>
                              <content styleCode="bold">Figure C</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 5.</content>
                           </td>
                           <td>If the dose requires more than 1 capsule shell, repeat <content styleCode="bold">Step 2</content> and <content styleCode="bold">Step 3</content>.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 6.</content>
                           </td>
                           <td>Gently mix the Oral Pellets with a spoon into the soft food. Note that the Oral Pellets will not dissolve (see <content styleCode="bold">
                                 <linkHtml href="#FigD">Figure D</linkHtml>
                              </content>).</td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2">
                              <renderMultiMedia referencedObject="MM7" ID="FigD"/>
                              <br/>
                              <content styleCode="bold">Figure D</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 7.</content>
                           </td>
                           <td>Give the entire dose right away after mixing. <content styleCode="bold">Do not</content> store the BYLVAY mixture for later use.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 8.</content>
                           </td>
                           <td>Give water or an age-appropriate liquid, such as breast milk or infant formula, after the dose is taken. </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 9.</content>
                           </td>
                           <td>	Dispose of (throw away) the empty Oral Pellet shells in the trash.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Giving BYLVAY Oral Pellets with liquids (Using an oral dosing syringe):</content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>The shell containing the Oral Pellets are to be opened.  </item>
                     <item>Mix the Oral Pellets with liquid as shown in <content styleCode="bold">Steps 1 through 14</content> below.</item>
                     <item>Dispose of (throw away) the emptied shells. <content styleCode="bold">Do not</content> let your child swallow the unopened shells containing the Oral Pellets.</item>
                  </list>
                  <table width="100%" styleCode="Noautorules">
                     <col width="8%" align="left" valign="top"/>
                     <col width="92%" align="left" valign="top"/>
                     <tbody>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 1.</content>
                           </td>
                           <td>Give BYLVAY with the first morning meal.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 2.</content>
                           </td>
                           <td>Hold the shell containing the Oral Pellets horizontally on both ends, twist in opposite directions and pull apart (see <content styleCode="bold">
                                 <linkHtml href="#FigA">Figure A</linkHtml>
                              </content>). </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 3.</content>
                           </td>
                           <td>Empty the Oral Pellets into a small mixing cup. Gently tap the Oral Pellet shell to ensure that all contents have been emptied into the mixing cup (see <content styleCode="bold">
                                 <linkHtml href="#FigE">Figure E</linkHtml>
                              </content>).</td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2">
                              <renderMultiMedia referencedObject="MM8" ID="FigE"/>
                              <br/>
                              <content styleCode="bold">Figure E</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 4.</content>
                           </td>
                           <td>If the dose requires more than 1 capsule shell, repeat <content styleCode="bold">Step 2</content> and <content styleCode="bold">Step 3</content>.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 5.</content>
                           </td>
                           <td>Add 1 teaspoon (5 mL) of an age-appropriate liquid (for example, breast milk, infant formula, or water).</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 6.</content>
                           </td>
                           <td>Let the pellets sit in the liquid for about 5 minutes to allow complete wetting. REMINDER: The pellets will not dissolve in the liquid.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 7.</content>
                           </td>
                           <td>After 5 minutes, place the tip of the oral syringe completely into the mixing cup. Pull the plunger of the syringe up slowly to withdraw the liquid and pellet mixture into the syringe. Gently push the plunger down again to expel the liquid and pellet mixture back into the mixing cup. Do this 2 to 3 times to ensure complete mixing of the pellets into the liquid.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 8.</content>
                           </td>
                           <td>Withdraw the entire contents into the syringe by pulling the plunger on the end of the syringe (see <content styleCode="bold">
                                 <linkHtml href="#FigF">Figure F</linkHtml>)</content>.</td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2">
                              <renderMultiMedia referencedObject="MM9" ID="FigF"/>
                              <br/>
                              <content styleCode="bold">Figure F</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 9.</content>
                           </td>
                           <td>Place the tip of the syringe into the front of the child's mouth between the tongue and the side of the mouth, and then gently push the plunger down to squirt the liquid and pellet mixture between the tongue and the side of the mouth. Do not squirt the liquid and pellet mixture in the back of the throat because this could cause gagging or choking (see <content styleCode="bold">
                                 <linkHtml href="#FigG">Figure G</linkHtml>)</content>.</td>
                        </tr>
                        <tr>
                           <td align="center" colspan="2">
                              <renderMultiMedia referencedObject="MM10" ID="FigG"/>
                              <br/>
                              <content styleCode="bold">Figure G</content>
                           </td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 10.</content>
                           </td>
                           <td>Do not give using a bottle or "sippy cup" because the Oral Pellets will not pass through the opening. The oral pellets will not dissolve in liquid.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 11.</content>
                           </td>
                           <td>Give water or an age-appropriate liquid such as breast milk or infant formula after the dose is taken.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 12.</content>
                           </td>
                           <td>Repeat Steps 8 and 9 until the entire dose has been given.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 13.</content>
                           </td>
                           <td>Check to make sure all of the liquid and pellet mixture has been swallowed.</td>
                        </tr>
                        <tr>
                           <td>
                              <content styleCode="bold">Step 14.</content>
                           </td>
                           <td>Dispose of (throw away) the empty Oral Pellet shells in the trash.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Taking BYLVAY Capsules </content>
                  </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Take BYLVAY Capsules <content styleCode="bold">along with your morning meal</content>. Swallow BYLVAY Capsules whole with a glass of water. <content styleCode="bold">Do not</content> chew or crush the Capsules.</item>
                     <item>For children unable to swallow BYLVAY Capsules whole, follow instructions under <content styleCode="bold">Preparing to Give BYLVAY</content> above.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How should I store BYLVAY Capsules or Oral Pellets?</content>
                  </paragraph>
                  <paragraph>Store BYLVAY at room temperature between 68°F to 77°F (20°C to 25°C).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Disposing (throwing away) of BYLVAY Capsules or Oral Pellets shells.</content>
                  </paragraph>
                  <paragraph>Dispose of (throw away) the empty BYLVAY Capsule or Oral Pellets shells in the household trash.</paragraph>
                  <paragraph>
                     <content styleCode="bold">What are the ingredients in BYLVAY?</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Active ingredient:</content> odevixibat.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Inactive ingredients:</content> hypromellose and microcrystalline cellulose. </paragraph>
                  <paragraph>Manufactured for: </paragraph>
                  <paragraph>Ipsen Biopharmaceuticals, Inc.<br/>One Main Street, <br/>Cambridge, MA 02142</paragraph>
                  <paragraph>© 2024 Ipsen Biopharmaceuticals, Inc. All rights reserved.</paragraph>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration. <br/>Revised: 01/2024</paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>Figure A</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Figure B</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Figure C</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Figure D</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Figure E</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Figure F</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM10">
                     <text>Figure G</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="ad660f3c-20af-4e99-b4e6-6fc455b64e44"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 200 mcg Capsule Bottle Carton</title>
               <text>
                  <paragraph>NDC 15054-3301-1</paragraph>
                  <paragraph>Bylvay<sub>®</sub>
                     <br/>(odevixibat)</paragraph>
                  <paragraph>ORAL PELLETS</paragraph>
                  <paragraph>200 mcg</paragraph>
                  <paragraph>RX ONLY<br/>30 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM11"/>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>Principal Display Panel - 200 mcg Capsule Bottle Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c9bb1c39-a450-4dc4-a08c-b87488650f89"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 400 mcg Capsule Bottle Carton</title>
               <text>
                  <paragraph>NDC 15054-3302-1</paragraph>
                  <paragraph>Bylvay<sub>®</sub>
                     <br/>(odevixibat)</paragraph>
                  <paragraph>CAPSULES</paragraph>
                  <paragraph>400 mcg</paragraph>
                  <paragraph>RX ONLY<br/>30 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM12"/>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="MM12">
                     <text>Principal Display Panel - 400 mcg Capsule Bottle Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="31ae51b0-ffc4-4960-81cf-dc8ecb8a43e9"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 600 mcg Capsule Bottle Carton</title>
               <text>
                  <paragraph>NDC 15054-3303-1</paragraph>
                  <paragraph>Bylvay<sub>®</sub>
                     <br/>(odevixibat)</paragraph>
                  <paragraph>ORAL PELLETS</paragraph>
                  <paragraph>600 mcg</paragraph>
                  <paragraph>RX ONLY<br/>30 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM13"/>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="MM13">
                     <text>Principal Display Panel - 600 mcg Capsule Bottle Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="977ddb5e-0c0e-4756-b0ee-8d3ae27aa0c5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 1,200 mcg Capsule Bottle Carton</title>
               <text>
                  <paragraph>NDC 15054-3304-1</paragraph>
                  <paragraph>Bylvay<sub>®</sub>
                     <br/>(odevixibat)</paragraph>
                  <paragraph>CAPSULES</paragraph>
                  <paragraph>1,200 mcg</paragraph>
                  <paragraph>RX ONLY<br/>30 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM14"/>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="MM14">
                     <text>Principal Display Panel - 1,200 mcg Capsule Bottle Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="bylvay-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>